How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,563 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Pharmaceutical ethnobotany in the Riverside of Navarra (Iberian Peninsula). (PubMed)

-structured interviews with 147 informants (mean age 76 years; the percentage of men and women was almost 50%) in 34 locations, identified the plants reported and analyzed the results, comparing them with those from other territories.The informants reported data on 90 medicinal plants belonging to 39 botanical families. This work is focused on human medicinal plant uses, which represent 99% of the pharmaceutical uses (541). The species with the highest number of cites are Santolina chamaecyparissus ssp (...) Pharmaceutical ethnobotany in the Riverside of Navarra (Iberian Peninsula). This paper provides significant ethnobotanical information on pharmaceutical plant uses in the Riverside of Navarra. Thereby, it will extend and complement a recent previous study carried out in the Northern Navarra. This paper aim to collect, analyse and evaluate the ethnobotanical knowledge about medicinal plants in the Riverside of Navarra (Iberian Peninsula) with 2554.4km(2) and 144,674 inhabitants.We performed semi

2011 Journal of Ethnopharmacology

162. Pharmaceutical ethnobotany in the Middle Navarra (Iberian Peninsula). (PubMed)

the results, comparing them with those from other territories.The informants reported data on 198 medicinal plants belonging to 60 botanical families. This work is focused on human medicinal plant uses, which represent 98% of the pharmaceutical uses (1401 use reports). The species with the highest number of cites are Santolina chamaecyparissus ssp. squarrosa, Jasonia glutinosa and Chamaemelum nobile with a long tradition of use in Navarra. All different plant parts are used; aerial part is exploited more (...) Pharmaceutical ethnobotany in the Middle Navarra (Iberian Peninsula). This paper provides significant ethnobotanical information on pharmaceutical plant uses in the Middle Navarra (Iberian Peninsula). Collect, analyze and evaluate the ethnobotanical knowledge about medicinal plants in this area with 3622.2 km(2) and 404,634 inhabitants.We performed semi-structured interviews with 276 informants (mean age 72; 46% women, 54% men) in 111 locations, identified the plant reported and analyzed

2011 Journal of Ethnopharmacology

163. Some Implications of Legalized Substitution of Prescribed Pharmaceuticals (Full text)

Some Implications of Legalized Substitution of Prescribed Pharmaceuticals In April 1962 the Alberta Government passed legislation permitting a pharmacist to substitute drugs on a written medical prescription unless the doctor indicated otherwise. The intent was stated to be in the interests of cheaper drugs for the people of Alberta. The legality of this legislature has been questioned in Federal courts of law. The legislation has been formally criticized by the official representatives

1962 Canadian Medical Association Journal PubMed

164. Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development (Full text)

Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development Within the European Immunogenicity Platform (EIP) ( http://www.e-i-p.eu ), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-PCS, review the current state of methods for analysis of protein aggregates. Moreover, we elaborate

2010 Pharmaceutical research PubMed

165. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. (Full text)

of this review is to examine the relationship between exposure to information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing.We searched for studies of physicians with prescribing rights who were exposed to information from pharmaceutical companies (promotional or otherwise). Exposures included pharmaceutical sales representative visits, journal advertisements, attendance at pharmaceutical sponsored meetings, mailed information, prescribing software (...) Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates that promotion may adversely influence prescribing, physicians hold a wide range of views about pharmaceutical promotion. The objective

2010 PLoS medicine PubMed

166. Pharmaceutical ethnobotany in Northern Navarra (Iberian Peninsula). (PubMed)

-structured interviews with 253 informants (mean age 69; 61% women, 39% men) in 120 locations, identified the plant reported and analyzed the results, comparing them with those from other territories.The informants reported data on 174 medicinal plants belonging to 63 botanical families. This work is focused on human medicinal plant uses, which represent 98% of the pharmaceutical uses (1725 use reports). The species with the highest number of cites are Chamaemelum nobile, Sambucus nigra and Verbena (...) Pharmaceutical ethnobotany in Northern Navarra (Iberian Peninsula). This paper provides significant ethnobotanical information on pharmaceutical plant uses in Northern Navarra from an area known both for its high biological diversity and its cultural significance, suggesting the survival of uses lost elsewhere. Collect, analyze and evaluate the ethnobotanical knowledge about medicinal plants in Northern Navarra (Iberian Peninsula) with 4243 km(2) and 71,069 inhabitants.We performed semi

2010 Journal of Ethnopharmacology

167. Pharmaceutical industry support and residency education: a survey of internal medicine program directors. (Full text)

Pharmaceutical industry support and residency education: a survey of internal medicine program directors. Interactions with the pharmaceutical industry are known to affect the attitudes and behaviors of medical residents; however, to our knowledge, a nationally representative description of current practices has not been reported.The Association of Program Directors in Internal Medicine surveyed 381 US internal medicine residency program directors in 2006-2007 regarding pharmaceutical industry (...) support to their training programs. The primary outcome measure was program director report of pharmaceutical financial support to their residency. Demographic and performance variables were analyzed with regard to these responses.In all, 236 program directors (61.9%) responded to the survey. Of these, 132 (55.9%) reported accepting support from the pharmaceutical industry. One hundred seventy of the 236 program directors (72.0%) expressed the opinion that pharmaceutical support is not desirable

2010 Archives of Internal Medicine PubMed

168. Hypertension in pregnancy: diagnosis and management

Hypertension in pregnancy: diagnosis and management Hypertension in pregnancy: diagnosis Hypertension in pregnancy: diagnosis and management and management NICE guideline Published: 25 June 2019 www.nice.org.uk/guidance/ng133 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) 10 years body mass index (BMI) of 35 kg/m 2 or more at first visit family history of pre-eclampsia multi-fetal pregnancy. [2010, amended 2019] [2010, amended 2019] Other pharmaceutical agents Other pharmaceutical agents 1.1.4 Do not use the following to prevent hypertensive disorders during pregnancy: nitric oxide donors progesterone diuretics low molecular weight heparin. [2010] [2010] Nutritional supplements Nutritional supplements 1.1.5 Do not recommend the following supplements solely

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

169. Heavy menstrual bleeding: assessment and management

Heavy menstrual bleeding: assessment and management Hea Heavy menstrual bleeding: assessment vy menstrual bleeding: assessment and management and management NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

170. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

171. Community pharmacies: promoting health and wellbeing

Services Negotiating Committee, which represents community pharmacy contractors. The framework includes a range of health-promoting services that community pharmacies should provide (Essential service 4 'Promotion of healthy lifestyles' and Essential service 5 'Signposting'). As part of the framework, pharmacies must participate in up to 6 public health campaigns each year at the request of NHS England (Public health [promotion of healthy lifestyles] Pharmaceutical Services Negotiating Committee (...) Community pharmacies: promoting health and wellbeing Community pharmacies: promoting Community pharmacies: promoting health and wellbeing health and wellbeing NICE guideline Published: 2 August 2018 nice.org.uk/guidance/ng102 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

172. Flu vaccination: increasing uptake

Flu vaccination: increasing uptake Flu vaccination: increasing uptak Flu vaccination: increasing uptake e NICE guideline Published: 22 August 2018 nice.org.uk/guidance/ng103 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) Consider working with statutory and voluntary organisations, including those representing people with relevant medical conditions, to increase awareness of flu vaccination among eligible groups (and their parents or carers, if relevant). 1.2.7 Give people who are eligible (or their parents or carers, if relevant) face-to-face brief advice or a brief intervention on the importance of flu vaccination. T ell them that they can have a free flu vaccination and explain why they are being offered it, using

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

173. [IBENTO][IBENTO]Report of the PMDA-ATC Medical Devices Seminar 2018

[IBENTO][IBENTO]Report of the PMDA-ATC Medical Devices Seminar 2018 Report of the PMDA-ATC Medical Devices Seminar 2018 | Pharmaceuticals and Medical Devices Agency Please make JavaScript on and see this site. Navigation of each product type Our recommended contents Navigation of each product type Our recommended contents Report of the PMDA-ATC Medical Devices Seminar 2018 Here begins the text. Report of the PMDA-ATC Medical Devices Seminar 2018 PMDA-ATC Medical Devices Seminar 2018 (...) Pharmaceuticals and Medical Devices Agency (PMDA) recently completed the PMDA-Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (ATC) Medical Devices Seminar 2018 on November 12-16, 2018. This seminar was designed for medical devices and in-vitro diagnostic products reviewers from overseas regulatory authorities. Total of 25 regulators from 17 countries/regions (i.e. Argentina, Azerbaijan, Bangladesh, Brazil, Cameroon, Ecuador, Hong Kong, India, Indonesia, Malaysia, Philippines

2019 Pharmaceuticals and Medical Devices Agency, Japan

174. Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V

for Quality and Efficiency in Health Care (IQWiG) - 1 - 2 Benefit assessment 2.1 Executive summary of the benefit assessment Background In accordance with §35a Social Code Book V, the Federal Joint Committee (G-BA) com- missioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug abiraterone acetate (hereinafter referred to as “abiraterone”). The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as “the company (...) with ADT was Extract of dossier assessment A17-64 Version 1.0 Abiraterone acetate (prostate cancer) 13 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 5 - shown in both studies. Due to the uncertainty to what extent the STAMPEDE study represents the target population, the LATITUDE study was primarily considered. Due to the high risk of bias for this outcome in the LATITUDE study, only a hint could be derived initially. Since the effect estimations of both studies pointed

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

175. Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V

by the pharmaceutical company (hereinafter referred to as “the company”). The dossier was sent to IQWiG on 15 February 2018. Research question The aim of the present report was the assessment of the added benefit of benralizumab in comparison with the appropriate comparator therapy (ACT) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus long-acting beta-agonists (LABAs). Table 2 shows the research (...) and possibly oral corticosteroids (OCS) c , or ? in case of IgE-mediated pathogenesis of asthma, possibly omalizumab d in addition to high-dose ICS and LABAs and possibly OCS c , or ? possibly of the high-dose ICS and LABAs with OCS c, e a: Presentation of the ACT specified by the G-BA. b: The Global Initiative for Asthma (GINA) graded scheme is to be taken into account. It is assumed that the therapeutic indication of benralizumab is represented in step 4 to step 5. Placebo or the unchanged continuation

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

176. Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug dupilumab. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as "the company"). The dossier was sent to IQWiG on 1 December 2017. Research question The aim of the present report was to assess the added benefit of dupilumab in comparison with the appropriate comparator therapy (ACT) in adult patients with moderate to severe atopic dermatitis who are candidates (...) to the CHRONOS study included in the present benefit assessment, the company considered another RCT in its assessment (R668-AD-1424; hereinafter referred to as CAFE). This study included adults with severe atopic dermatitis for whom systemic treatment with ciclosporin was not indicated. Thus, the study population of the CAFE study represented a subpopulation of the approval population of dupilumab. However, due to the short treatment duration (16 weeks), the CAFE study considered by the company is unsuitable

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

177. Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56

Code Book V [SGB V]) [1]. In Module 4 of its dossier on cabozantinib [2], the pharmaceutical company (hereinafter referred to as “the company”) presented the METEOR study for the therapeutic indication of advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)- targeted therapy. The METEOR study was used for the benefit assessment. However, the responder analyses for the morbidity outcome “symptoms” presented by the company, represented by the Functional Assessment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

178. Managing opioid use disorder in primary care: PEER simplified guideline

Eli Orrantia MD MSc CCFP FCFP Kim Reich RSW Nick Wong MD CCFP(AM) FCFP Nicolas Dugré PharmD MSc Adrienne J. Lindblad ACPR PharmD Abstract Objective To use the best available evidence and principles of shared, informed decision making to develop a clinical practice guideline for a simplified approach to managing opioid use disorder (OUD) in primary care. Methods Eleven health care and allied health professionals representing various practice settings, professions, and locations created a list (...) | MAI 2019 CLINICAL PRACTICE GUIDELINES The PEER simplified guideline provides a primary care per - spective and substantial adjunctive content to support pri- mary care practitioners and shared, informed decision making with patients. —— Methods —— As with previous PEER guidelines, 19,20 we followed the principles of the Institute of Medicine’s Clinical Practice Guidelines We Can Trust. 21 Thirteen individuals, representing various practices, locations across Canada, and experience with manag- ing

2019 CPG Infobase

179. British guideline on the management of asthma

interests It has been recognised that financial interests in, or close working relationships with, pharmaceutical companies may have an influence on the interpretation of evidence from clinical studies. It is not possible to completely eliminate any possible bias from this source, nor even to quantify the degree of bias with any certainty. SIGN requires that all those involved in the work of guideline development should declare all financial interests, whether direct or indirect, annually for as long (...) ), therefore, represent consensus opinion, building on the overarching principles defined in section 3.1. It is further informed by the evidence available from these pragmatic studies combined with data from the diagnostic studies described in section 3.2. There is an urgent need for diagnostic accuracy studies and implementation research to confirm, prospectively, the diagnostic accuracy of retrospectively-derived algorithms and to define the optimal approach to making a diagnosis in different clinical

2019 SIGN

180. Impact of pharmaceutical representative visits on GPs' drug preferences. (Full text)

Impact of pharmaceutical representative visits on GPs' drug preferences. Pharmaceutical representative visits are believed to have substantial impact, but the effects on prescribing patterns have not been systematically evaluated.This study investigates how pharmaceutical sales representative visits influenced physicians' company-specific drug preferences and prevalence of steroid prescribing.Observational cohort study in Funen County, Denmark, including 165 general practices visited 832 times (...) by pharmaceutical representatives and 54 080 patients treated with asthma drugs. Visits were conducted from 2001 to 2003. Our main outcome measures were (i) company-specific drug preferences measured as the proportion of dispensings of the promoted drug among all dispensings of fixed combinations of inhaled corticosteroid and long-acting beta2-agonists and (ii) the proportion of patients receiving repeated beta2-agonist dispensings who were treated with inhaled steroids.The first visit had a statistically

2009 Family Practice PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>